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ABSTRACT
Aim To test the contribution of programmed cell death 4
(PDCD4) tumour suppressor gene in Barrett’s
carcinogenesis.
Methods PDCD4 immunohistochemical expression was
assessed in 88 biopsy samples obtained from
histologically proven long-segment Barrett’s mucosa
(BM; 25 non-intestinal columnar metaplasia, 25 intestinal
metaplasia (IM), 16 low-grade intraepithelial neoplasia
(LG-IEN), 12 high-grade IEN (HG-IEN) and 10 Barrett’s
adenocarcinoma (BAc)). As controls, 25 additional
samples of native oesophageal mucosa (N) were
obtained from patients with dyspepsia. To further
support the data, the expression levels of miR-21, an
important PDCD4 expression regulator, in 14 N, 5
HG-IEN and 11 BAc samples were determined by
quantitative real-time PCR analysis.
Results PDCD4 immunostaining decreased progressively
and signiﬁcantly with the progression of the phenotypic
changes occurring during Barrett’s carcinogenesis
(p<0.001). Normal basal squamous epithelial layers
featured strong PDCD4 nuclear immunoreaction (mostly
coexisting with weakemoderate cytoplasmic staining).
Non-intestinal columnar metaplasia and intestinal
metaplasia preserved a strong nuclear immunostaining;
conversely, a signiﬁcant decrease in PDCD4 nuclear
expression was seen in dysplastic (LG-IEN and HG-IEN)
and neoplastic lesions. Weakemoderate cytoplasmic
immunostaining was evident in cases of LG-IEN, while
HG-IEN and BAc samples showed weak cytoplasmic or
no protein expression. As expected, miR-21 expression
was signiﬁcantly upregulated in HG-IEN and BAc
samples, consistently with PDCD4 dysregulation.
Conclusions These data support a signiﬁcant role for
PDCD4 downregulation in the progression of BM to BAc,
and conﬁrm miR-21 as a negative regulator of PDCD4 in
vivo. Further efforts are needed to validate PDCD4 as
a potential prognostic marker in patients with Barrett’s
oesophagus.
INTRODUCTION
In many western countries, the incidence of
Barrett’s adenocarcinoma (BAc) has dramatically
increased over the last two decades. Barrett’s
oesophagus (BE) is deﬁned as the replacement of
squamous oesophageal epithelium by columnar
intestinalised mucosa (Barrett’s mucosa, BM) and
this metaplastic transformation is recognised as the
cancerisation ﬁeld in which BAc develops.
1e3
Many investigators have focused on which histo-
pathological characteristics of BE have malignant
potential, and which factors promote Barrett’sc a r c i -
nogenesis. The histological diagnosis of dysplasia
(deﬁned as low-grade or high-grade intraepithelial
neoplasia (IEN or NiN)) is currently considered the
only biomarker for deﬁning high-risk BE
populations.
4e6 The identiﬁcation of additional
molecular markers of cancer progression might
support strategies for cancer secondary prevention
and/or provide a biological rationale for targeted
therapies.
A growing number of reports have pointed to
PDCD4 (programmed cell death 4) as a new tumour
suppressor gene.
7e13 PDCD4 is a 64 kDa protein
involved in the apoptotic machinery, which
suppresses cell transformation, tumorigenesis and
invasion.
7e13 Different mechanisms have been
implicated in the control of the steady-state and
subcellular location of PDCD4. Among others, the
oncogenic microRNA miR-21 (hsa-miR-21) has
been shown to speciﬁcally target the PDCD4
39-UTR, which negatively regulates PDCD4
expression.
14e19
P D C D 4e x p r e s s i o ni ss i g n i ﬁcantly downregulated
in various human cancers, as well as in cancer cell
lines, and this has been associated with a poor patient
prognosis.
19e24 PDCD4 protein levels have been
found to be inversely correlated with miR-21 expres-
sion in oesophageal squamous cell carcinoma cell
lines,
18 a n dw eh a v es h o w nt h a tP D C D 4e x p r e s s i o ni s
signiﬁcantly downregulated in oesophageal cancers
(adenocarcinoma and squamous cell carcinoma
histotypes) and it predicts patient outcome.
25
To test the role of PDCD4 in contributing to
oesophageal carcinogenesis, we investigated PDCD4
immunohistochemical expression in Barrett’s carci-
nogenesis. We also examined miR-21 expression
levels in high-grade IEN (HG-IEN) and BAc samples
by quantitative real-time PCR (qRT-PCR analysis).
MATERIALS AND METHODS
cDNA microarray analysis
The Oncomine database and gene microarray
analysis tool, a repository for published cDNA
microarray data (http://www.oncomine.org/),
26 27
was explored (on 15 December 2009) for PDCD4
mRNA expression in non-neoplastic oesophageal
tissues, BM and primary BAc. Oncomine algo-
rithms were used to perform a statistical analysis of
the differences in PDCD4 expression, since it allows
for multiple comparisons among different stud-
ies.
26e28 Only studies with analytical results with
ap <0.05 were considered.
Patients
The cases in the present study were retrospectively
collected from the ﬁles of the Veneto Region’s
multicentre Barrett’s Oesophagus Registry (EBRA;
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29 selecting cases of histologically proven, long-
segment BE. A total of 88 biopsy samples of oesophageal mucosa
were obtained from different patients with BE, that is, 25 with
non-intestinal columnar metaplasia (cardiac-type columnar
metaplasia), 25 with intestinal metaplasia (Barrett’s mucosa), 16
with low-grade intraepithelial neoplasia (LG-IEN), 12 with high-
grade IEN (HG-IEN), and 10 with BAc. Another 25 native
oesophageal mucosa samples (N) were obtained from patients
with dyspepsia who had no gastro-oesophageal disease at
endoscopy/histology (from the ﬁles at the Surgical Pathology
Unit of the University of Padova). For the qRT-PCR study, 2 mm
cores were obtained from parafﬁn blocks selected from 14
consecutive patients who had undergone oesophagectomy at the
Department of Gastroenterological and Surgical Sciences,
University of Padova, for HG-IEN and/or BAc, giving a total of
14 N, 5 HG-IEN and 11 BAc samples. None of the patients had
received neoadjuvant therapy. Written consent was obtained
from all the patients involved in the study.
Histological and immunohistochemical study
All biopsy specimens were immediately ﬁxed in 10% buffered
formalin and embedded in parafﬁn wax. Serial histological
sections 4e6 mm thick were obtained from each parafﬁn wax
block and stained with H&E and Alcian-PAS. The original
diagnosis was conﬁrmed on the histological evidence in all cases.
Immunohistochemical staining was done automatically
(Ventana Benchmark XTsystem; Ventana, Touchstone, Arizona,
USA)
30 for PDCD4 (1:100; catalogue no. HPA001032; Atlas
Antibodies, Stockholm, Sweden) according to the manufac-
turer’s instructions. Sections were lightly counterstained with
haematoxylin. Appropriate positive and negative controls were
run concurrently. In cancer samples, the presence of positive
stromal and inﬂammatory cells served as an internal control.
PDCD4 expression was jointly scored by two pathologists (MF
and MR) who were unaware of the patients’ clinical history.
Consistent with Mudduluru et al,
22 nuclear and cytoplasmic
immunoreactions were considered. Nuclear PDCD4 staining
results were classiﬁed in four groups according to the percentage
of positively stained nuclei: score 0, none; score 1, #30%; score
2, 30e70%; score 3, $70%. Cytoplasmic PDCD4 expression was
scored by staining intensity (score 0, none; score 1, weak; score
2, intermediate; score 3, strong). Atotal score was also calculated
as the sum of the nuclear and cytoplasmic scores, and cases were
divided into four groups, deﬁned as: negative (total score 0),
weak staining (total score 1 or 2), intermediate staining (total
score 3 or 4), and strong staining (total score 5 or 6).
Quantitative real-time PCR
Tissue cores were deparafﬁnised with xylene at 508C for 3 min.
Total RNA extraction was done using the RecoverAll kit
(Ambion, Austin, Texas, USA) according to the manufacturer’s
instructions. The NCodeTM miRNA qRT-PCR method (Invi-
trogen, Carlsbad, California, USA) was used to detect and
quantify mature miR-21 (primer sequence: 59-CGGTAGCT-
TATCAGACTGATGTTGA-39) on real-time PCR instruments
according to the manufacturer’s instructions (Applied
Figure 1 Expression array analysis of multiple available Barrett’s
oesophageal adenocarcinoma microarray data sets was performed for
PDCD4, calculating the statistical signiﬁcance, using the Oncomine
database and gene microarray data analysis tool.
31e33 PDCD4
expression in normal tissues (Normal), Barrett’s mucosa (BM) and
esophageal adenocarcinomas (BAc) is shown. Class analysis:
Wang_Esophagus (correlation¼ 0.614; p¼1.3310
 6; 24 normal, 19
BM, 9 BAc)
32; Hao_Esophagus (correlation¼ 0.656; p¼8.4 1310
 5;
15 normal, 14 BM, 5 BAc)
33; Kimchi_Esophagus (correlation¼ 0.665;
p¼4.0310
 4; 8 normal, 8 BM, 8 BAc).
31
Figure 2 Immunohistochemical (IHC) staining scores for PDCD4.
Nuclear PDCD4 immunostaining was signiﬁcantly weaker in high-grade
intraepithelial neoplasia (HG-IEN) and Barrett’s adenocarcinoma (BAc)
lesions. Cytoplasmic PDCD4 expression was stronger in low-grade
intraepithelial neoplasia (LG-IEN), but weaker in HG-IEN and BAc. The
combined (total) PDCD4 staining scores were signiﬁcantly lower in
preneoplastic/neoplastic lesions (LG-IEN, HG-IEN and BAc) than in
normal (N) and metaplastic tissues (non-intestinal columnar metaplasia
(GM); intestinal metaplasia (IM)) (p<0.001).
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done with the small nuclear RNA U6B (RNU6B; Invitrogen).
PCR reactions were run in triplicate, including no-template
controls. The data were analysed using the comparative CT
method.
Statistical analysis
KruskaleWallis test, Student t test and Pearson’s correlation
tests were used to analyse differences and correlations between
groups; p values <0.05 were considered signiﬁcant. All the
statistical analyses were done with Stata software (Stata
Corporation, College Station, Texas, USA).
RESULTS
The PDCD4 gene is downregulated in Barrett’s carcinogenesis
PDCD4 gene expression was analysed by checking different
publicly available BE microarray studies using the Oncomine
database and gene microarray data analysis tools.
26 27 The
analysis considered the mRNA expression levels for each of the
studies involved, and the signiﬁcance of the expression of the
gene across the studies considered was also taken into account.
In the three independent data sets of human Barrett’s oeso-
phageal carcinogenesis considered, PDCD4 mRNA expression
levels decreased signiﬁcantly when primary BAc was compared
versus BE and versus native squamous epithelium (Pearson’s
correlation p¼1.98310
 4)
31e33 (ﬁgure 1).
PDCD4 expression is downregulated in BAc
The normal basal squamous epithelial layer (proliferative zone)
consistently featured strong PDCD4 nuclear expression (mostly
coexisting with weak-moderate cytoplasmic staining; ﬁgures 2
and 3). In normal and cancer tissue samples, non-cancerous and
non-epithelial cells (ﬁbroblasts, lymphocytes, smooth muscle cells
and endothelia) always featured PDCD4 nuclear expression (this
ﬁnding was considered as a positive internal control and it did not
interfere with the histological assessment).
19 22 34 35 PDCD4
nuclear downregulation was consistently found in dysplastic and
neoplastic lesions (KruskaleWallis p<0.001). In particular,
moderateestrong nuclear staining was always associated with
non-intestinal columnar metaplasia and intestinal metaplasia
(scoring 2/3 in 24/25 and 23/25 cases, respectively), whereas
intraepithelial (LG and HG) and invasive neoplasia showed
as i g n i ﬁcantly lower PDCD4 nuclear expression (scores 2/3: 5/16,
0/12 and 0/10, respectively). Weakemoderate cytoplasmic
staining was apparent in LG-IEN (scores 1/2: 15/16); HG-IEN and
BAc samples showed weak cytoplasmic or no protein expression
(score 1: 10/12 and 4/10, respectively). Overall, PDCD4 levels
decreased progressively and signiﬁcantly with the dedifferentia-
tion of the lesions considered (KruskaleWallis p<0.001).
miR-21 is overexpressed in HG-IEN and BAc
It has been demonstrated that PDCD4 is regulated directly by the
oncomiR miR-21, with a 100% match sequence at nt228-249
(ﬁgure 4A).
14e19 The PDCD4 39-UTR miR-21 target sequence is
highly conserved among different species,
14 so we investigated
miR-21 expression in preneoplastic and neoplastic Barrett’s
lesions. When we determined miR-21 expression levels in 14 N, 5
HG-IEN and 11 BAc samples (ﬁgure 4B), a signiﬁcant miR-21
upregulation was found in the HG-IEN (with a 2.3-fold increase; t
test p<0.001) and BAc (with a twofold increase; t test p<0.001).
DISCUSSION
The progression of BM to BAc passes through well-established
histological changes, in which dysplasia is considered the most
advanced phenotypic change before invasive cancer sets in.
1 23 6
However, not all dysplastic lesions progress to cancer, and
a better understanding of the molecular biology of this disease
may lead to improvements in the diagnosis, treatment and
prognosis of patients with BE.
37
PDCD4 has been characterised as a new tumour suppressor
gene, which is downregulated in several human malignancies.
19e24
Its overexpression inhibits neoplastic transformation in both
cancer cell lines and in vivo models.
10 38 39
Low PDCD4 protein levels (assessed by western blot and qRT-
PCR analyses) have been observed in oesophageal squamous cell
carcinoma cell lines.
18 In a large series of oesophageal tumours,
we recently found that PDCD4 protein was completely lost or
signiﬁcantly reduced in almost 60% of the tumour samples
Figure 3 Representative PDCD4 immunostainings of non-cancer oesophageal tissues and preneoplastic/neoplastic lesions in the Barrett’s
carcinogenic cascade. In native squamous oesophageal epithelium, normal oesophageal basal cells feature strong nuclear and weakemoderate
cytoplasmic staining. Non-intestinal columnar metaplasia (GM) and intestinal metaplasia (IM) preserved a strong nuclear immunostaining.
Weakemoderate cytoplasmic immunostaining was seen in cases of in low-grade intraepithelial neoplasia (LG-IEN), whereas in high-grade
intraepithelial neoplasia (HG-IEN) and Barrett’s adenocarcinoma (BAc) samples showed weak cytoplasmic or no protein expression. Note the presence
in the HG-IEN and BAc examples of PDCD4-nuclear positive residual GM/IM glands (black arrows) (original magniﬁcations 320 and 340).
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25 As in the lung cancer setting,
20 no signiﬁcant
difference in PDCD4 dysregulation was observed between the
two main histotypes of oesophageal cancer (adenocarcinoma
(Barrett related and non-Barrett related) versus squamous cell
carcinoma). Moreover, nuclear PDCD4 expression was associ-
ated with longer disease-free and overall survival rates.
25
Hence we performed this study, which explored the immu-
nohistochemical expression of PDCD4 in a series of Barrett-
related lesions. PDCD4 protein expression was consistently lost/
reduced in almost all HG-IEN and BAc tissue samples. In fact,
the combined (nuclear and/or cytoplasmic) PDCD4 expression
decreased signiﬁcantly as the lesions considered became more
dedifferentiated.
In particular, PDCD4 nuclear expression was signiﬁcantly
downregulated in preneoplasticeneoplastic tissue samples by
comparison with normal metaplastic tissues. On the other hand,
LG-IEN showed a weakemoderate cytoplasmic immunostaining.
These data strongly suggest that the intracellular localisation of
PDCD4 (as assessed by immunohistochemistry) is a useful addi-
tional diagnostic tool in the clinical and biological characterisation
of BE-related lesions. A similar nuclear-to-cytoplasmic shift was
documented by Mudduluru et al
22 in colorectal carcinogenesis.
The biological interpretation of the subcellular expression of
the protein remains inconsistent. In vitro studies have shown
that, under normal growth conditions, PDCD4 is located mainly
in the nucleus, moving to the cytoplasm on serum withdrawal.
7
The nuclear-to-cytoplasm shift documented in preneoplastic/
neoplastic lesions could theoretically result from epigenetic
(and/or genetic) gene dysregulation.
In oesophageal squamous carcinoma cell lines, Hiyoshi et al
recently demonstrated that PDCD4 gene expression is regulated
by miR-21.
18 We observed a signiﬁcant upregulation of miR-21
in HG-IEN and BAc. miR-21 is overexpressed in different human
cancers, being causally linked to cell proliferation, apoptosis and
migration.
14e19 miR-21 was also found to be upregulated in both
oesophagealadenocarcinomaandsquamouscellcarcinoma,
18 40 41
suggesting a major oncogenic function for miR-21 (acquired early
in both of these oncogenic pathways).
In conclusion, our ﬁndings consistently point to PDCD4 being
a promising biomarker in the identiﬁcation of cancer-prone BM-
related lesions. The association of PDCD4 with more traditional
immunohistochemistry markers (and p53 in particular) may be
useful in the routine histological assessment of BM-related lesions.
In addition, the evidence of PDCD4 and miR-21 involvement in
Barrett’s carcinogenesis represents a solid biological rationale for
innovative targeted therapy.
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